Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro by unknown
PRECLINICAL STUDIES
Effects of mTOR inhibitors and cytoskeletal-directed agents alone
and in combination against normal and neoplastic hematopoietic
cells in vitro
Matthew Trendowski1 & Timothy D. Christen1 & Antoaneta A. Andonova1 &
Berlini Narampanawe1 & Ashlee Thibaud1 & Tenzin Kusang1 & Thomas P. Fondy1
Received: 30 August 2015 /Accepted: 7 October 2015 /Published online: 22 October 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Summary The mechanistic target of rapamycin (mTOR)
controls cell growth and enlargement and has been found to
be aberrant in a wide variety of malignancies. Although
mTOR is already an attractive antineoplastic target, overex-
pression or aberrant expression of mTORmay also provide an
opportunity to further increase the size differential between
malignant and normal cells, providing an opportunity to am-
plify and exploit cell size differences between neoplastic cells
and their normal counterparts using physiochemical treatment
modalities. Therefore, this study sought to quantify the con-
centration response and time course effects of rapamycin on
cell cycle entry, cell enlargement, and cell proliferation in
U937 human monocytic leukemia and human hematopoietic
stem cells (hHSCs). In addition, the effects of combination
treatment with mTOR inhibitors (rapamycin, everolimus,
and temsirolimus) and cytoskeletal-directed agents (cytocha-
lasin B and vincristine) in leukemic cells (U937, THP1, K562,
Molt-4, and L1210) were assessed for potential drug synergy.
While both U937 cells and hHSCs exhibited a marked reduc-
tion in cell volume, U937 cells were able to proliferate in the
presence of rapamycin ranging from 0.5 nM to 10 μM (10,
000 nM), whereas hHSCs were able to proliferate only at
lower concentrations, and were completely inhibited from
proliferation by 8 nM rapamycin. These effects were observed
with as little as 0.5 nM rapamycin, demonstrating the pro-
found affinity the compound has for FK-binding protein 12
(FKBP12), which subsequently forms the FKBP12/
rapamycin complex to inhibit mTOR. Rapamycin continued
to exert effects on cell size and proliferation even at 10 μM,
without producing marked cytotoxicity. Although cytochala-
sin B and vincristine were unable to substantially enlarge
rapamycin-treated leukemia cells, it appears that rapamycin
and its associated analogs everolimus and temsirolimus have
notable synergistic potential with microfilament-disrupting
cytochalasin B and microtubule-disrupting vincristine as
assessed by comparative effects on cell growth, annexin V
staining, IC30 isobolograms, and Chou-Talalay statistics.
These observations indicate a potentially novel therapeutic
rationale for hematological malignancies and for other cancers
to elicit the preferential destruction of neoplastic cells that
aberrantly express mTOR.
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Introduction
The mechanistic target of rapamycin (mTOR) has received
considerable attention as a potential target for cancer chemo-
therapy. As a member of the phosphatidylinositol 3-kinase-
related kinase protein (PIKK) family, mTOR is a serine/
threonine protein kinase that regulates cell growth, cell prolif-
eration, cell motility, cell survival, protein synthesis, and tran-
scription, and is a constituent of the PI3K/AKT/mTOR (PI3K:
phosphatidylinositol-4,5-bisphosphate 3-kinase; AKT: pro-
tein kinase B) pathway [1]. Due to its substantial regulatory
control on normal cellular function, mutations involving the
mTOR pathway considerably increase the likelihood of carci-
nogenesis. Indeed, aberrant mTOR regulation has been found
in a considerable diversity of cancer types, including breast,
lung, and pancreatic carcinomas, as well as hematological
malignancies [2–5]. These studies have confirmed that
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mTOR is indeed a commonly aberrant pathway constituent in
malignant cells, contributing substantially to the pathogenesis
of many malignancies. As such, virtually all research involv-
ing the mTOR pathway has been directed toward inhibiting
mTOR as a key oncoprotein. This is to be expected, as onco-
genes and their associated oncoproteins facilitate cancer pa-
thology through increasing growth and proliferation, as well
as establishing an immortalized cellular phenotype [6].
However, there are other approaches to obtaining
preferential damage against malignant cells. It is well
known that malignant cells have a perturbed cytoskele-
ton due to the effects of dysplasia and subsequent ana-
plasia [6]. With so many alterations present in malig-
nant cells, the cytoskeleton provides an ideal opportuni-
ty to obtain preferential damage through a physical mo-
dality. While neoplastic cells have a considerable pro-
pensity to acquire drug resistance to persistent chemo-
therapeutic exposure, it is very difficult for cytoskeletal
integrity to be reinforced after exposure to a physical
d is turbance [6, 7] . In an approach known as
sonodynamic therapy (SDT), specialized chemotherapeu-
tic agents known as sonosensitizers are administered to
increase the extent of preferential damage elicited by
ultrasound against neoplastic cells. It has been repeated-
ly shown that ultrasound preferentially damages malig-
nant cells based on the size differential between such
cells and those of normal histology [7–12]. This known
fact suggests that enlarging neoplastic cells to increase
their already noticeable size difference with normal cells
could be a method by which to attain further preferen-
tial damage.
Since overexpression of mTOR has been extensively asso-
ciated with increased proliferation rates in hematological ma-
lignancies, exploiting the aberrant pathway may be a potential
approach to further increase the size differential between nor-
mal and neoplastic cells. mTOR acquired its name due to its
profound sensitivity to rapamycin, a bacterial toxin produced
by Streptomyces hygroscopicus [13, 14]. Although the true
binding target of rapamycin is FK-binding protein 12
(FKBP12), the FKBP12/rapamycin complex potently inhibits
the function of mTORC1, and to a certain extent mTORC2.
Initially, rapamycin (sirolimus) was employed as an immuno-
suppressive drug following organ transplantation, as it sup-
presses mammalian immune systems by blocking the G1 to
S phase transition in T-lymphocytes [13, 14]. Therefore,
rapamycin inhibition of mTOR prevents normal immune-
response cells from completing mitosis by preventing cell
cycle progression. Since its introduction as an immunosup-
pressive agent, the antineoplastic activity of rapamycin has
been widely noted, and its derivatives everolimus and
temsirolimus are used in the clinical setting for the treatment
of localized solid tumors, as well as disseminated cancers
[1–4]. However, it may be the case that leukemias and other
hematological malignancies have acquired enough mutations
to become resistant to rapamycin exposure. As such, the ma-
lignant cells would continue through the cell cycle and com-
plete mitosis, thereby amplifying the already substantial size
difference between leukemic and normal blood cells. Further,
it is likely that cell enlarging microfilament- and microtubule-
directed agents that severely perturb mitosis could consider-
ably amplify this size difference, potentially enhancing the
efficacy of these agents.
Exploiting aberrant mTOR signaling in leukemias and oth-
er hematological malignancies may indeed provide a reliable
basis to preferentially enlarge malignant cells under physio-
logical conditions. Such size differences may be exploited by
physicochemical therapeutic approaches that specifically tar-
get large cells with weakened cytoskeletal integrity. Therefore,
this study seeks to compare the physiological responses of
malignant and normal blood cells after exposure to rapamycin.
In addition, normal and neoplastic hematopoietic cells are
treated with cell enlarging cytoskeletal-directed agents (cyto-
chalasin B and vincristine) alone and in combination with
mTOR inhibitors (rapamycin, everolimus and temsirolimus)
to determine whether marked preferential enlargement and
damage of leukemic cells can be attained.
Materials and methods
Preparation of leukemia cell lines and normal blood cells
U937 human monocytic leukemia cells (ATCC® CRL-
1593.2) were placed at 5.2 × 104 viable cells/ml in 20 % fetal
bovine serum (FBS) in Iscove’s medium without glutamine,
with the following added: 200 units/ml penicillin, 200 μg/ml
streptomycin, 100 μg/ml gentamicin sulfate, 40 μM gluta-
mine (50 μl of 2 mM glutamine per 5 ml medium), and
50 μl of amphotericin B (2.5 μg/ml concentration) per 5 ml
of medium. K562, Molt-4, and THP1 human leukemia
(ATCC® CCL-243, CRL-1582, TIB-202), as well as L1210
murine leukemia (ATCC® CCL-219) were cultured under the
same conditions. Human hematopoietic stem cells (hHSCs)
acquired from the State University of New York Upstate
Medical University (Syracuse, NY, USA) were cultured under
the same conditions after their use was approved by an IRB
protocol. Cells were incubated in 5 % CO2 in a humidified
chamber at 37 °C. Viability was assessed by 0.4 % trypan blue
stain in isotonic saline, followed by cell counting and sizing
using a Z2 Beckman-Coulter® Particle Count and Size
Analyzer (Beckman Coulter Inc., Brea, CA, USA), along with
a Bio-Rad® TC20 Automated Cell Counter (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). Extent of
multinucleation after treatment with rapamycin or
cytoskeletal-directed agents was assessed with Wright stain.
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MTOR inhibitor preparation and administration
Rapamycin (Sigma-Aldrich Corp., St. Louis, MO, USA)
was prepared in 40 μM stock solutions using 95 %
EtOH (Sigma-Aldrich Corp.). Rapamycin analogs evero-
limus and temsirolimus were prepared using the same
conditions. Cell size, viability, and proliferation rates
were determined by the cell counters. Vehicle controls
of 95 % EtOH were tested in parallel with the
rapamycin-treated cells.
Effects of cytoskeletal-directed agents on rapamycin
activity
8 nM vincristine was administered for an additional 25 h
after cells were exposed to 10 μM rapamycin for 24 h.
The 10 μM rapamycin was removed prior to vincristine
administration, but due to the high concentration of
rapamycin prior to removal, a residual concentration of
40 nM rapamycin was left in solution, along with the
8 nM vincristine. Vincristine-treated U937 cells were
then compared to controls that received only rapamycin
to determine whether cell size effects of rapamycin
could be affected by the microtubule-altering agent in
neoplastic or normal cells. 4 nM vincristine and 2 μM
cytochalsin B were similarly tested with a 12 h and
48 h exposure, respectively after treatment with 50 nM
rapamycin for 24 h.
Effects of concomitant administration of mTOR inhibitors
and cytoskeletal-directed agents against normal
and neoplastic hematopoietic cells
To assess the cytotoxic effects of rapamycin and two of its
associated analogs (everolimus and temsirolimus; Sigma-
Aldrich Corp.) with cytochalasin B and vincristine, multiple
leukemia cell lines (U937, THP1, K562, Molt-4, and L1210
were exposed to vary ing concent ra t ions of the
abovementioned mTOR inhibitors and cytoskeletal-directed
agents, both alone and in combination. Cytotoxicity was
assessed by comparative effects on cell growth and annexin
V staining (Life Technologies, Grand Island, NY, USA).
Potential drug synergy was evaluated with IC30
isobolograms (IC30 values were chosen due to the fact
that rapamycin did not inhibit U937 cell growth beyond
approximately 44 %). In addition, the Chou-Talalay
method for assessing drug synergism was implemented
to determine the combination index (CI) and fraction
affected (Fa). As indicated in [15], drug synergy was
assessed with the following values: CI < 1 (synergism),
CI = 1 (additive), and CI > 1 (antagonism).
Results
Effects of 48 hour rapamycin treatment on the cell size
of U937 human monocytic leukemia and human
hematopoietic stem cells
The effects of rapamycin at concentrations ranging from
0.5 to 32 nM are shown in Table 1. The differential
effect of rapamycin on the sizes of normal and leukemic
cells was apparent at concentrations at and below
32 nM, with differential inhibition amounting to 2-fold
based on cell volume percent reduction (Table 1).
Nevertheless, both U937 cells and hHSCs appeared to
have a marked reduction in size 48 h after rapamycin
administration at 25 nM or higher (Table 2). As seen in
Table 2, 25 nM rapamycin inhibited hHSC cell size by
24 %, while U937 cells were reduced by only 12 %,
suggesting that the leukemia cells were more resistant to
the effects of rapamycin at or below 25 nM. At 25 nM
rapamycin, the leukemia cells remained quite large with
an average volume of 1829 μm3, while hHSCs had an
average volume of 698 μm3. The effects of rapamycin
on cell size were concentration-dependent from 25 nM
to 200 nM for U937 cells, but not for hHSCs. Size
reduction for U937 cells remained at 30 % at 400 nM
and 800 nM rapamycin. For hHSCs, size was reduced
by as much as 31 % at 50 nM, with the size inhibition
leveling off at higher concentrations. It should be noted
that the average cell volume for untreated U937 cells
and hHSCs was 15 % larger in Table 2 compared to
Table 1 due to different times of cell growth, with the
distribution of cells at slightly different places in the
cell cycle.
The effects of rapamycin on the average volume of hHSCs
are further highlighted in Fig. 1a. While 0.48 % EtOH ap-
peared to partially reduce hHSC volume (Fig. 1a), the size
Table 1 Effects of rapamycin concentrations ranging from 0.5 to
32 nM on the average cell volume of U937 human monocytic leukemia


















0 1800 0 742 0
0.5 1798 0.02 760 −0.24
1 1763 2.1 723 2.6
2 1752 2.7 704 5.2
4 1740 3.4 702 5.4
8 1710 5 668 10
16 1675 7 632 14.8
32 1543 14.3 601 19.1
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reduction was minimal, whereas rapamycin from 25 nM
to 400 nM produced size reductions from 23 % to 30 %
with EtOH concentrations of 0.48 %. Figure 1b shows
the effects on average cell volume of leukemia cells
treated with rapamycin under conditions identical with
the rapamycin treatment of hHSCs shown in Fig. 1a.
The EtOH vehicle at 0.48 % had a minimal influence
on the cell volume of U937 cells ≥8 μm and ≥13 μm.
25 nM rapamycin reduced the volume of U937 cells
≥13 μm by only 10 %, and increasing the concentration
of rapamycin from 50 nM to 800 nM reduced U937 cell
volume for cells of the same size range by ~20 %, but
no concentration dependence was observed. For U937
cells ≥8 μm, the size reduction was ~22 % with con-
centrations of rapamycin ranging from 50 nM to
800 nM (Fig. 1b). Therefore, rapamycin concentrations
up to 800 nM enhanced or maintained the already large
2 to 2.5-fold size differential between hHSCs and U937
cells.
Proliferation of U937 human monocytic leukemia
and human hematopoietic stem cells in the presence
of rapamycin from 0.5 nM to 10,000 nM
It appeared that U937 cells, but not hHSCs, readily proliferat-
ed in a 72 h growth assay in the presence of rapamycin from
0.5 nM to 32 nM (Fig. 2a). Untreated U937 cells increased 8-
fold in 72 h, while rapamycin-treated cells exhibited a 5 to 7-
fold increase at rapamycin concentrations as high as 32 nM.
By contrast, untreated hHSCs doubled in 72 h, but had very
low rates of proliferation after treatment with 1 nM to 4 nM
rapamycin, and were completely inhibited by rapamycin at
8 nM to 32 nM.
To determine the effects of rapamycin at concentra-
tions above 32 nM, separate U937 cell populations were
studied under concentrations of rapamycin ranging from
0.5 nM to 10,000 nM (10 μM) for times of 48 to 51 h,
60 to 72 h, or 96 h (Fig. 2b). The results of this anal-
ysis indicated that U937 cells continue to proliferate in
the presence of rapamycin at all concentrations from
0.5–100 nM, and remain able to proliferate with slight
growth inhibition at concentrations as high as 10 μM.
Untreated U937 cells increased 6-fold in 48 to 51 h, 8-
fold in 60 to 72 h, and 23-fold in 96 h. In the presence
of 10 μM rapamycin, U937 cells were still able to pro-
liferate 6-fold in a 96 h assay. Further, rapamycin did
not affect leukemia cell proliferation substantially at
0.5 nM and 1 nM, but did reduce growth in a
concentration-dependent fashion from 2 nM to 25 nM.
From 25 nM to 10 μM, rapamycin still permitted U937
cell proliferation, allowing treated populations to reach
33–80 % of the proliferation levels obtained with un-
treated cells. These data suggest that the size and pro-
liferation of hHSCs can be inhibited by rapamycin con-
centrations that are markedly less inhibitory toward
U937 cells.
Effects of rapamycin-treated U937 cell enlargement
following vincristine or cytochalasin B administration
8 nM vincristine appeared to have a notable influence on the
size of U937 cells previously treated with 10 μM rapamycin
for 24 h (Fig. 3a). The average size of the population appeared
to markedly increase after vincristine exposure for 22 or 25 h
in the presence of residual rapamycin (the dilution to remove
10 μM left a residual rapamycin concentration of ~40 nM, as
indicated in Fig. 3a). This demonstrates that rapamycin-
treated leukemia cells can increase in size after exposure to
the microtubule-directed agent. By contrast, U937 cells treat-
ed for 24 h with 10 μM rapamycin followed by rapamycin
removal to 40 nM, but not exposed to vincristine, remained
substantially reduced in size for up to 45 h (Fig. 3b).
Nevertheless, these data indicate that rapamycin/vincristine
treated leukemia cells do not reach the extent of enlargement
observed after treatment with only vincristine (Fig. 4a). A
similar pattern is observed when U937 cells are exposed to
2 μM cytochalasin B for 48 h, as rapamycin/cytochalasin B
treated cells are larger than those only treated with rapamycin,
but are not nearly as large as cells treated only with cytocha-
lasin B (Fig. 4b). Interestingly, rapamycin/cytochalasin B
treated U937 cells do not exhibit the high rates of
multinucleation that is elicited by cytochalasin B-alone treat-
ments, even when rapamycin is administered at 2 nM for 48 h
(Figs. 4b and c). This is in accord with the cell size data shown
in Fig. 4b, as rapamycin/cytochalasin B treated cells have a
substantially smaller size range than cytochalasin B treated
cells, indicating that cell enlargement induced by
multinucleation is not as prevalent.
Table 2 Effects of rapamycin concentrations ranging from 25 to
800 nM on the average cell volume of U937 human monocytic



















0 2083 0 900 0
25 1829 12 698 24
50 1536 24 619 31
100 1500 28 682 24
200 1480 29 645 28
400 1458 30 715 21
800 1462 30 672 25
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Effects of mTOR inhibitors and cytoskeletal-directed
agents alone and in combination against normal
and neoplastic hematopoietic cells
As illustrated in Fig. 5a, concomitant administration of
rapamycin and either cytochalasin B or vincristine perturbed
cell viability in all leukemia cell lines examined (U937, THP1,
K562, Molt-4, and L1210) much greater than any of the single
agent treatments. Of particular note, the percentage of THP1
cells compared to untreated controls dropped from 73.3 %
with administration of 50 nM rapamycin to 24.5 % and
48.9 % when combined with either 2 μM cytochalasin B or
4 nM vincristine. By comparison, monotherapy with cytocha-
lasin B or vincristine elicited only 54.6 % and 64.7 %,
Fig. 1 Comparison of rapamycin-induced size reduction between human
hematopoietic stem cells and U937 human monocytic leukemia. a
Average hHSC volume 48 h post-rapamycin administration. All hHSCs
were ≥8 μm prior to treatment. b Average U937 large and small cell
volumes 48 h post-rapamycin administration. Large cells (≥ 13 μm) are
denoted with red columns, while small cells (≥ 8 μm) are denoted with
blue columns. The effects of 0.48 % EtOH on cell size appear to be
minimal. Bars represent the standard error of the mean (SEM) for each
individual treatment group.
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respectively of the untreated controls. Further, K562 and
L1210 were markedly damaged by rapamycin/cytochalasin
B or vincristine treatments, despite being notably resistant to
all of the single agent treatments, indicative of potentially
favorable drug interactions. Concomitant administration
of rapamycin/cytochalasin B appeared to potentiate the
most damage in all leukemia cell lines, except Molt-4 in
which rapamycin/vincristine produced the lowest cell
count. Interestingly, the combinatorial effects of
rapamycin and cytoskeletal-directed agents were
reproduced in all of the leukemic cell lines when
rapamycin was replaced with another mTOR inhibitor
(either everolimus or temsirolimus; Fig. 5b). These ef-
fects were achieved with as little as 2 nM everolimus or
temsirolimus, indicative of the potential cytotoxic boost
cytoskeletal-directed agents may elicit in combination
with mTOR inhibitors. As with rapamycin, it appeared
that cytochalasin B potentiated more favorable cytotoxic
interaction with everolimus and temsirolimus in
comparision to vincristine combinations, thereby produc-
ing the lowest cell counts in all leukemia cell lines
examined.
The cell viability data were in accord with the annexin V
apoptosis assay, as concomitant administration of rapamycin
Fig. 2 Effects of rapamycin on human hematopoietic stem cell and U937
human monocytic leukemia cell proliferation. a Comparison between
U937 cells and hHSCs on proliferation rates after exposure to varying
concentrations of rapamycin for 72 h. U937 cells are denoted by solid
bars, while hHSCs are denoted by hatched bars. Bars represent SEM for
each individual treatment group. b Time-course study of the effect of
rapamycin from 0 to 10,000 nM on U937 cell proliferation. Each line
represents the hour post-rapamycin administration at which cell prolifer-
ation was observed.
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and cytoskeletal-directed agents appeared superior to mono-
therapy in potentiating apoptotic signaling. As in Fig. 5a,
THP1 was particularly sensitive to concomitant chemothera-
py, as rapamycin/cytochalasin B produced a 50.1 % apoptosis
rate, while rapamycin/vincristine produced a 31.4% apoptosis
rate. In addition, rapamycin/cytochalasin B produced a higher
apoptotic rate in all cell lines examined (U937, K562, and
THP1) than rapamycin/vincristine, further indicative of
unique interactions between mTOR and microfilament
inhibition.
Assessment of drug synergy between rapamycin
and cytoskeletal-directed agents
Rapamycin appeared to synergize with both cytochalasin B
and vincristine against U937, THP1, and K562 cells when
combined IC30 values were plotted to form isobolograms
(Fig. 6). However, cytochalasin B interacted more favorably
with rapamycin than did vincristine, as the curves underneath
the additivity lines were more pronounced, particularly with
THP1. Similar results were attained with Chou-Talalay Fa-CI
Fig. 3 Effects of 8 nM vincristine on rapamycin-treated U937 cells. a
Effects of 8 nM vincristine for 25 h on U937 cells treated for 24 h with
10 μM rapamycin followed by rapamycin removal prior to vincristine
addition. Residual rapamycin estimated at 40 nM after rapamycin
removal by dilution. b Extent of cell size recovery of U937 cells after
removal of 10 μM rapamycin (to a residual 40 nM) with no vincristine
added. Large cells (≥ 13 μm) are denoted with red columns, while small
cells (≥ 8 μm) are denoted with blue columns. Bars are SEM of three
individual cell populations at different time points.
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plots (Fig. 6), with many of the rapamycin/cytochalsin B CI
points falling in the strong synergism (0.1–0.3) to synergism
(0.3–0.7) range, while rapamycin/vincristine CI points often
fell in the upper limits of synergism, as well as the moderate
synergism (0.7–0.85) range. The potential for increased syn-
ergy between rapamycin and cytochalasin B may be the result
of the inhibitory effects these agents have on microfilaments,
which will be elaborated upon in the discussion.
Discussion
Rapamycin produced a 24 % reduction in the cell size of
hHSCs at 25 nM after 48 h of exposure, and produced a
31 % reduction at 50 nM after the same length of exposure
(Table 2). Under these conditions, reduction in cell size for
U937 cells was only 12 % for 25 nM and 24 % for 50 nM.
This tentatively suggests that rapamycin reduces cell size
more in hHSCs than in U937 cells at lower concentrations
of rapamycin. Therefore, when both cell populations are com-
pared directly for size reduction after treatment with
rapamycin, U937 cells can override the rapamycin treatment
under conditions that remain inhibitory for hHSCs. In addi-
tion, U937 cells retained the ability to proliferate in the pres-










Fig. 4 Effects of rapamycin and cytoskeletal-directed agents on cell size
of U937 human monocytic leukemia cells. a Size distribution of U937
cells following treatment with rapamycin and vincristine alone and in
combination. b Size distribution of U937 cells following treatment with
rapamycin and cytochalasin B alone and in combination. Abbreviations
used are as follows: CB (cytochalasin B), NT (not treated), Rapa
(rapamycin), and VCR (vincristine). c Photomicrograph of U937 cells
treated with 2 nM Rapa and 2 μM CB for 48 h. d) Photomicrograph of
U937 cells treated with 2 μMCB for 48 h. Photomicrographs were taken
at 400× after being Wright stained.
Fig. 5 Effects of rapamycin and associated analogs in combination with
cytoskeletal-directed agents against normal and neoplastic hematopoietic
cells. a Multiple leukemia cell lines were treated with 50 nM Rapa for
72 h alone and in combination with either 2 μM CB for 48 h or 4 nM
VCR for 12 h. b Multiple leukemia cell lines were treated with Rapa
analogs everolimus (Ever; 2 nM for 72 h) and temsirolimus (Tem;
2 nM for 72 h) alone and in combination with 2 μM CB for 48 h or
4 nM VCR for 12 h. c Annexin V apoptosis assay for U937, K562, and
THP1 cells after being treated with rapamycin, cytochalasin B, and
vincristine-alone and in combination. Treatment concentrations and
durations are indicated in the panel. Bars represent SEM for each
individual treatment group.
b
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were no longer able to proliferate at 8 nM after the same length
of exposure (Fig. 2). Further, U937 cells were able to recover
from rapamycin exposure, as the percent proliferation was
dramatically increased at concentrations ranging from
0.5 nM to 10 μM once the length of exposure was extended
to 96 h (Fig. 2b).
These observations suggest that aberrant mTOR signaling
in U937 cells may enable such populations to become more
resistant to the inhibitory effects of rapamycin compared to
normal cell populations. This differential effect of rapamycin
on leukemia cells may be related to the overexpression of
mTORC1 and potentially mTORC2 in the neoplastic cells,
allowing the leukemic cells to proliferate under conditions that
reduce the size of hHSCs and drive the normal cells from the
cell cycle. Therefore, rapamycin may be able to prevent cell
enlargement and proliferation of normal cells under conditions
that allow neoplastic cells to enlarge, replicate their nuclei, and
potentially multinucleate when treated with microfilament-
directed agents that inhibit cytokinesis, although
multinucleation was not readily observed in rapamycin/
cytochalasin B treated cells (Fig. 4c). This differential effect
could protect the small resting normal cells from treatments
that damage enlarged, multinucleated, dividing neoplastic
cells.
However, it is important to note that rapamycin still pro-
duced a substantial reduction in U937 cell size (24% at 50 nM
and 30 % at 800 nM after 48 h of exposure), and that concen-
trations of rapamycin ≥200 nM inhibited the cell size of U937
cells more than hHSCs, suggesting that mTOR function can
be potently inhibited in U937 cells at higher concentrations of
rapamycin. Consequently, 10 μM rapamycin-treated U937
cells are unable to substantially recover to normal cell sizes,
even 45 h after rapamycin has been removed (note: 40 nM
residual rapamycin remained after removal). Although the ad-
dition of 8 nM vincristine to rapamycin-treated leukemia cells
was enough to nearly restore typical cell sizes observed in
populations not treated with rapamycin (Fig. 3b), the
cytoskeletal-directed agent was unable to induce the high
amount of cell enlargement that is observed with the addition
of vincristine as a monotherapy (Fig. 4a).
As assessed through cell viability and drug synergy analy-
ses, mTOR inhibitors (rapamycin, everolimus, and
CB/Rapa IC30 Isobolograms 
and Fa-CI Plot 
a
Fig. 6 Assessment of drug synergy between rapamycin and cytoskeletal-
directed agents against multiple leukemia cell lines after 48 h of
continuous exposure through isobolographic analysis and Chou-Talalay
method Fa-CI plots. a IC30 isobolograms and Fa-CI plot for CB/Rapa
against U937, THP1, and K562 human leukemia cells. b IC30
isobolograms and Fa-CI plot for VCR/Rapa against the same cell lines.
According to the Chou-Talalay method for the assessment of drug
synergy [15], < 0.1 (very strong synergism), 0.1–0.3 (strong
synergism), 0.3–0.7 (synergism), 0.7–0.85 (moderate synergism), 0.85–
0.9 (slight synergism) are all values of synergism, while 0.9–1.1 may be
considered additive or potentially antagonistic, and any values greater
than 1.1 are antagonistic.
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temsirolimus) interact favorably with cytochalasin B and vin-
cristine against all of the leukemic cell lines examined in the
present study (U937, THP1, K562, Molt-4, and L1210;
Figs. 5 and 6). However, these data also suggest that cytocha-
lasin B may elicit more synergistic potential with mTOR in-
hibitors than does vincristine, as most, but not all, neoplastic
cell populations were inhibited greater with mTOR inhibitor/
cytochalasin B administration (Fig. 5). In addition, rapamycin/
cytochalasin B elicited more prominent synergistic interac-
tions than rapamycin/vincristine against U937, THP1, and
K562 (Fig. 6). The efficacy of rapamycin/vincristine combi-
nations has been previously described, as it has been
shown than rapamycin can markedly sensitize vincris-
tine resistant cells to the microtubule-directed agent
[16]. Further, the concomitant administration of mTOR
inhibitors/vincristine has been demonstrated to be much
more effective against multiple murine xenograft models
of malignancy than the respective standard agents used
alone at their maximum tolerated doses (MTDs) [17,
18]. However, the present study is the first to demon-
strate the potential utility of cytochalasin B and possibly
other microfilament-directed agents in combination with
mTOR inhibitors, and future preclinical studies should
be directed towards a more extensive examination of
this unique antineoplastic strategy.
Although the underlying mechanistic interactions that pro-
mote rapamycin/cytochalasin B drug synergy are not fully
elucidated in the present study, it is known that mTORC2 is
involved in promoting actin polymerization, thereby enabling
the formation of filamentous (F)-actin stress fibers [19–21]. In
addition, mTORC2 regulates the actin cytoskeleton through
its stimulation of paxillin, RhoA, Rac1, Cdc42, and protein
kinase C α (PKCα) [22]. While low concentrations of
rapamycin preferentially inhibit mTORC1 rather than
mTORC2, the compound begins to inhibit mTORC2 under
prolonged exposure [23–25]. Disrupting the formation of F-
actin has deleterious effects on the cytoskeletal integrity of
cells [26, 27], suggesting that rapamycin should be able to
act in concert with cytoskeletal-disrupting antineoplastic
agents, and enhance the combined cytotoxicities of both clas-
ses of agents. Further, since inhibiting the formation of viable
microfilaments through the administration of cytochalasin B
dramatically increases the ultrasonic sensitivity of multiple
leukemia cells, concomitant administration of rapamycin and
cytochalasin B is likely to induce synergistic ultrasonic sensi-
tization. Indeed, we have performed preliminary experiments
that indicate rapamycin, everolimus, and temsirolimus admin-
istered at concentrations as low as 2 nM potentiate the ultra-
sonic sensitivity of human leukemia cells, a notion that will be
elaborated upon in a subsequent study.
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It should be noted that while cytoskeletal-directed agents
enhanced the cytotoxicity of mTOR inhibitors, as well as en-
larged U937 cells treated with rapamycin, concomitant admin-
istration of rapamycin and cytoskeletal-directed agents may
preclude significant increases in neoplastic cell size, as is ob-
served when either cytochalasin B or vincristine are adminis-
tered as single agents (Fig. 4a; 12, 27]). Nevertheless, we have
also determined that the mechanism by which cytoskeletal-
directed agents induce cell enlargement is vital for their ulti-
mate potentiation of ultrasonic sensitivity, with agents that
inhibit polymerization eliciting a much greater effect than
those that enhance and stabilize formed cytoskeletal polymers
[27, 28]. Therefore, concomitant administration of cytochala-
sin B and/or vincristine with mTOR inhibitors will likely po-
tentiate marked ultrasonic sensitization.
The present study suggests that rapamycin and
cytoskeletal-directed agents may potentiate clinically applica-
ble drug synergy, while concurrently inducing a slight, but
noticeable preferential increase of malignant cell size in the
presence of their normal counterparts. As indicated by the
study, rapamycin should be administered first, effectively
deactivating the proliferation potential of normal blood cells.
Then, cell enlarging cytoskeletal-directed agents that act dur-
ing mitotic events can be applied to preferentially affect ac-
tively proliferating neoplastic cells. Such concomitant chemo-
therapy may increase the substantial size difference between
malignant cells and those of normal histology; the exact fea-
ture by which SDT preferentially damages neoplastic tissue.
Regardless of their potential use as sonosensitizers,
rapamycin, everolimus, and temsirolimus all appear to dem-
onstrate enhanced cytotoxicity when used in combination
with cytochalasin B or vincristine. Further characterizing the
potential antineoplastic applications of mTOR inhibitors and
cytoskeletal-directed agents using in vivo preclinical mamma-
lian models of malignancy is therefore warranted.
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